标题
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
作者
关键词
-
出版物
Current Obesity Reports
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-01-07
DOI
10.1007/s13679-020-00422-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Morbid Obesity as an Independent Risk Factor for COVID‐19 Mortality in Hospitalized Patients Younger than 50
- (2020) Eyal Klang et al. Obesity
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- (2020) Robert F. Kushner et al. Obesity
- Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity
- (2020) Harold E. Bays et al. Obesity
- Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus
- (2020) Steven B. Heymsfield et al. Obesity
- The risk of cardiovascular complications with current obesity drugs
- (2020) Ariana M. Chao et al. Expert Opinion On Drug Safety
- Obesity, eating behavior and physical activity during COVID-19 lockdown: A study of UK adults
- (2020) Eric Robinson et al. APPETITE
- Overcoming obesity: Weight-loss drugs are underused
- (2020) Amjad Kanj et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial
- (2020) John Sharretts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nutritional intervention strategies for the management of overweight and obesity in primary health care: A systematic review with meta‐analysis
- (2020) Raquel Canuto et al. Obesity Reviews
- Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
- (2019) Natasha C. Bergmann et al. DIABETOLOGIA
- The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
- (2019) Yan‐Ling He et al. DIABETES OBESITY & METABOLISM
- Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study
- (2019) Preeshila Behary et al. DIABETES CARE
- Cardiovascular risk and obesity
- (2019) C. Cercato et al. Diabetology & Metabolic Syndrome
- Current and emerging therapies for managing hyperphagia and obesity in Prader‐Willi syndrome: A narrative review
- (2019) Qiming Tan et al. Obesity Reviews
- Updates on obesity pharmacotherapy
- (2018) Amanda Velazquez et al. Annals of the New York Academy of Sciences
- Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial
- (2018) Michael A. Nauck et al. DIABETES CARE
- Centrally Acting Agents for Obesity: Past, Present, and Future
- (2018) Ann A. Coulter et al. DRUGS
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Maintenance of Lost Weight and Long-Term Management of Obesity
- (2018) Kevin D. Hall et al. MEDICAL CLINICS OF NORTH AMERICA
- Obesity Pharmacotherapy
- (2018) Katherine H. Saunders et al. MEDICAL CLINICS OF NORTH AMERICA
- Safety and tolerability of new-generation anti-obesity medications: a narrative review
- (2018) Dhiren K Patel et al. POSTGRADUATE MEDICINE
- Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach
- (2018) Bethany A. Falls et al. ACS Chemical Neuroscience
- Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
- (2018) Gül Bahtiyar et al. Current Diabetes Reports
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Persistence of newer anti-obesity medications in a real-world setting
- (2018) Rahul Ganguly et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Cardiovascular Safety During and After Use of Phentermine and Topiramate
- (2018) Mary E Ritchey et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
- (2018) Erin A Bohula et al. LANCET
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Gregory A Roth et al. LANCET
- Pharmacotherapy of obesity: Available medications and drugs under investigation
- (2018) Eleni Pilitsi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters
- (2018) Michael B. Zemel et al. Obesity
- Gender-related issues in the pharmacology of new anti-obesity drugs
- (2018) Mauro Cataldi et al. Obesity Reviews
- Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK
- (2018) Krishnan Bhaskaran et al. Lancet Diabetes & Endocrinology
- Effects of Metreleptin in Pediatric Patients With Lipodystrophy
- (2017) Rebecca J. Brown et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers
- (2017) Tricia Tan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Combination therapy for obesity
- (2017) John PH Wilding JOURNAL OF PSYCHOPHARMACOLOGY
- Mechanisms, Pathophysiology, and Management of Obesity
- (2017) Steven B. Heymsfield et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
- (2017) Tinh-Hai Collet et al. Molecular Metabolism
- FDA-Approved Anti-Obesity Drugs in the United States
- (2016) Homayoun L. Daneschvar et al. AMERICAN JOURNAL OF MEDICINE
- Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy
- (2016) Jean L. Chan et al. CLINICAL ENDOCRINOLOGY
- Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
- (2016) Per Lundkvist et al. DIABETES OBESITY & METABOLISM
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
- (2016) Olivia M. Farr et al. DIABETOLOGIA
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
- (2016) Rohan Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials
- (2016) Irene Romera et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s
- (2016) Catherine E. Thomas et al. Obesity
- Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers
- (2016) Ken Fujioka et al. Obesity
- GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7
- (2015) Jacqueline A. Koehler et al. Cell Metabolism
- Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives
- (2015) Beverly G Tchang et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010
- (2015) Ying Xia et al. Obesity
- Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy
- (2015) Cristina Adelia Meehan et al. Expert Review of Clinical Pharmacology
- A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats
- (2014) Kim V. Andreassen et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- 20 YEARS OF LEPTIN: Human disorders of leptin action
- (2014) I Sadaf Farooqi et al. JOURNAL OF ENDOCRINOLOGY
- Phentermine/Topiramate for the Treatment of Obesity
- (2013) Steven M Smith et al. ANNALS OF PHARMACOTHERAPY
- Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
- (2013) A. E. Butler et al. DIABETES
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Metreleptin: First Global Approval
- (2013) Ken Chou et al. DRUGS
- Inhibition of ghrelin O-acyltransferase attenuates food deprivation-induced increases in ingestive behavior
- (2013) Brett J.W. Teubner et al. HORMONES AND BEHAVIOR
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
- (2013) M E J Lean et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs
- (2013) Herbert Y. Meltzer et al. JOURNAL OF CLINICAL INVESTIGATION
- Training Physicians to Manage Obesity — Back to the Drawing Board
- (2013) James A. Colbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Risk of colorectal cancer after initiation of orlistat: matched cohort study
- (2013) J.-L. Hong et al. BMJ-British Medical Journal
- Chronic Treatment With a Melanocortin-4 Receptor Agonist Causes Weight Loss, Reduces Insulin Resistance, and Improves Cardiovascular Function in Diet-Induced Obese Rhesus Macaques
- (2012) P. Kievit et al. DIABETES
- The FDA's Assessment of Two Drugs for Chronic Weight Management
- (2012) Eric Colman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Double-Blind, Placebo-Controlled Study of an Oral, Extended-Release Formulation of Phentermine/Topiramate for the Treatment of Obstructive Sleep Apnea in Obese Adults
- (2012) David H. Winslow et al. SLEEP
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes
- (2011) RJ Bailey et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
- (2010) A Sjödin et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial
- (2010) Louis J. Aronne et al. Obesity
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- Prevention of Overweight and Obesity: How Effective is the Current Public Health Approach
- (2010) Ruth S.M. Chan et al. International Journal of Environmental Research and Public Health
- AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
- (2009) Carles Cantó et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started